Abstract

ABSTRACT

Sodium–glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and renal outcomes in chronic kidney disease patients with and without diabetes. Kidney transplant recipients have been excluded from landmark trials using SGLT2is and literature on safety and efficacy are scarce. Recent studies suggest that the SGLT2i use in kidney transplant recipients with diabetes is safe, paving the way to investigate whether SGLT2is could also reduce cardiovascular events and kidney function deterioration in kidney allograft recipients.

Details

Title
Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
Author
Oliveras, Laia 1 ; Montero, Núria 1 ; Cruzado, Josep M 1   VIAFID ORCID Logo 

1  N ephrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat , Catalonia, Spain 
Pages
909-913
Publication year
2023
Publication date
Jun 2023
Publisher
Oxford University Press
ISSN
20488505
e-ISSN
20488513
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1093/ckj/sfad045
ProQuest document ID
3171846797
Copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.